Immunic Past Earnings Performance
Past criteria checks 0/6
Immunic's earnings have been declining at an average annual rate of -21.8%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-21.8%
Earnings growth rate
17.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -235.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Immunic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -97 | 18 | 78 |
| 30 Jun 24 | 0 | -95 | 18 | 76 |
| 31 Mar 24 | 0 | -98 | 17 | 79 |
| 31 Dec 23 | 0 | -94 | 16 | 83 |
| 30 Sep 23 | 0 | -129 | 16 | 85 |
| 30 Jun 23 | 0 | -127 | 15 | 81 |
| 31 Mar 23 | 0 | -125 | 16 | 77 |
| 31 Dec 22 | 0 | -120 | 15 | 71 |
| 30 Sep 22 | 0 | -85 | 15 | 69 |
| 30 Jun 22 | 0 | -83 | 14 | 68 |
| 31 Mar 22 | 0 | -79 | 14 | 67 |
| 31 Dec 21 | 0 | -93 | 13 | 61 |
| 30 Sep 21 | 0 | -83 | 13 | 54 |
| 30 Jun 21 | 0 | -77 | 13 | 49 |
| 31 Mar 21 | 0 | -70 | 11 | 44 |
| 31 Dec 20 | 0 | -44 | 10 | 39 |
| 30 Sep 20 | 0 | -41 | 18 | 33 |
| 30 Jun 20 | 0 | -36 | 18 | 30 |
| 31 Mar 20 | 0 | -39 | 16 | 26 |
| 31 Dec 19 | 0 | -35 | 15 | 23 |
| 30 Sep 19 | 0 | -32 | 5 | 21 |
| 30 Jun 19 | 0 | -26 | 3 | 15 |
| 31 Mar 19 | 0 | -14 | 3 | 11 |
| 31 Dec 18 | 0 | -12 | 2 | 10 |
| 30 Sep 18 | 0 | -10 | 2 | 9 |
| 31 Dec 17 | 0 | -10 | 1 | 9 |
| 31 Dec 16 | 0 | -1 | 1 | 1 |
Quality Earnings: 10VA is currently unprofitable.
Growing Profit Margin: 10VA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 10VA is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare 10VA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 10VA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 10VA has a negative Return on Equity (-235.1%), as it is currently unprofitable.